[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EP3856195A4 - Procédés et compositions pour traiter des troubles liés au vieillissement au moyen d'inhibiteurs de ccr3 - Google Patents

Procédés et compositions pour traiter des troubles liés au vieillissement au moyen d'inhibiteurs de ccr3 Download PDF

Info

Publication number
EP3856195A4
EP3856195A4 EP19867321.2A EP19867321A EP3856195A4 EP 3856195 A4 EP3856195 A4 EP 3856195A4 EP 19867321 A EP19867321 A EP 19867321A EP 3856195 A4 EP3856195 A4 EP 3856195A4
Authority
EP
European Patent Office
Prior art keywords
ccr3
inhibitors
compositions
methods
treating aging
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19867321.2A
Other languages
German (de)
English (en)
Other versions
EP3856195A1 (fr
Inventor
Steven P. Braithwaite
S. Sakura Minami
Karoly Nikolich
Sanket V. Rege
Arnaud E.J. TEICHERT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alkahest Inc
Original Assignee
Alkahest Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkahest Inc filed Critical Alkahest Inc
Publication of EP3856195A1 publication Critical patent/EP3856195A1/fr
Publication of EP3856195A4 publication Critical patent/EP3856195A4/fr
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP19867321.2A 2018-09-26 2019-09-25 Procédés et compositions pour traiter des troubles liés au vieillissement au moyen d'inhibiteurs de ccr3 Pending EP3856195A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862737017P 2018-09-26 2018-09-26
PCT/US2019/052995 WO2020069008A1 (fr) 2018-09-26 2019-09-25 Procédés et compositions pour traiter des troubles liés au vieillissement au moyen d'inhibiteurs de ccr3

Publications (2)

Publication Number Publication Date
EP3856195A1 EP3856195A1 (fr) 2021-08-04
EP3856195A4 true EP3856195A4 (fr) 2022-06-22

Family

ID=69953286

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19867321.2A Pending EP3856195A4 (fr) 2018-09-26 2019-09-25 Procédés et compositions pour traiter des troubles liés au vieillissement au moyen d'inhibiteurs de ccr3

Country Status (16)

Country Link
EP (1) EP3856195A4 (fr)
JP (2) JP7528065B2 (fr)
KR (1) KR20210065950A (fr)
CN (1) CN112789044A (fr)
AU (1) AU2019346456A1 (fr)
BR (1) BR112021004938A2 (fr)
CA (1) CA3111433A1 (fr)
CL (1) CL2021000724A1 (fr)
CO (1) CO2021003713A2 (fr)
EA (1) EA202190463A1 (fr)
IL (1) IL281578A (fr)
MA (1) MA53743A (fr)
MX (1) MX2021002967A (fr)
SG (1) SG11202102105VA (fr)
TW (1) TW202027752A (fr)
WO (1) WO2020069008A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005090330A1 (fr) * 2004-03-22 2005-09-29 Astrazeneca Ab Derives de n-piperidine utilises en tant que modulateurs ccr3
US20130266646A1 (en) * 2012-04-04 2013-10-10 Boehringer Ingelheim International Gmbh Pharmaceutical formulations comprising ccr3 antagonists
US20160208011A1 (en) * 2010-01-28 2016-07-21 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
WO2018187503A1 (fr) * 2017-04-05 2018-10-11 Alkahest, Inc. Méthodes et compositions destinées à traiter des troubles associés au vieillissement à l'aide d'inhibiteurs de ccr3
WO2018187473A1 (fr) * 2017-04-05 2018-10-11 Alkahest Inc. Méthodes et compositions pour traiter une maladie associée à la rétine à l'aide d'inhibiteurs de ccr3

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1996551A2 (fr) * 2006-03-07 2008-12-03 AstraZeneca AB Derives de piperidine, leur procede de preparation, leur utilisation comme agents therapeutiques et compositions pharmaceutiques les contenant
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
AR076362A1 (es) 2009-04-22 2011-06-08 Axikin Pharmaceuticals Inc Arilsulfonamidas 2,5-disustituidas antagonistas de ccr3, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento y/o prevencion de patologias autoinmunes e inflamatorias, entre otras.
UA109290C2 (uk) * 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005090330A1 (fr) * 2004-03-22 2005-09-29 Astrazeneca Ab Derives de n-piperidine utilises en tant que modulateurs ccr3
US20160208011A1 (en) * 2010-01-28 2016-07-21 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
US20130266646A1 (en) * 2012-04-04 2013-10-10 Boehringer Ingelheim International Gmbh Pharmaceutical formulations comprising ccr3 antagonists
WO2018187503A1 (fr) * 2017-04-05 2018-10-11 Alkahest, Inc. Méthodes et compositions destinées à traiter des troubles associés au vieillissement à l'aide d'inhibiteurs de ccr3
WO2018187473A1 (fr) * 2017-04-05 2018-10-11 Alkahest Inc. Méthodes et compositions pour traiter une maladie associée à la rétine à l'aide d'inhibiteurs de ccr3

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
REGE S ET AL: "Abstracts from the 13th International Conference on Cerebral Vascular Biology (CVB 2019)", FLUIDS AND BARRIERS OF THE CNS, vol. 16, no. S1, 1 June 2019 (2019-06-01), XP093106172, Retrieved from the Internet <URL:http://link.springer.com/article/10.1186/s12987-019-0135-8/fulltext.html> DOI: 10.1186/s12987-019-0135-8 *
See also references of WO2020069008A1 *

Also Published As

Publication number Publication date
CN112789044A (zh) 2021-05-11
AU2019346456A1 (en) 2021-04-15
JP2024153742A (ja) 2024-10-29
CO2021003713A2 (es) 2021-04-08
BR112021004938A2 (pt) 2021-06-01
MX2021002967A (es) 2021-08-11
MA53743A (fr) 2022-01-05
WO2020069008A1 (fr) 2020-04-02
CL2021000724A1 (es) 2021-10-15
TW202027752A (zh) 2020-08-01
SG11202102105VA (en) 2021-04-29
JP2022502441A (ja) 2022-01-11
EP3856195A1 (fr) 2021-08-04
JP7528065B2 (ja) 2024-08-05
EA202190463A1 (ru) 2021-06-29
IL281578A (en) 2021-05-31
CA3111433A1 (fr) 2020-04-02
KR20210065950A (ko) 2021-06-04

Similar Documents

Publication Publication Date Title
EP3606525A4 (fr) Méthodes et compositions destinées à traiter des troubles associés au vieillissement à l&#39;aide d&#39;inhibiteurs de ccr3
EP3823673A4 (fr) Compositions anti-cd112r et procédés
EP3924490A4 (fr) Procédés de traitement de la cholestase
EP3297702A4 (fr) Méthodes et compositions permettant de traiter des troubles associés au vieillissement
EP3735325A4 (fr) Compositions et procédés de traitement de surface
EP3852608A4 (fr) Compositions et méthodes destinées à traiter le glaucome
EP3307296A4 (fr) Procédés et compositions pour traiter des états associés au vieillissement
IL290840A (en) Preparations and methods for altering cd123
EP3931336A4 (fr) Compositions et procédés de traitement de laminopathies
EP3687524A4 (fr) Compositions et méthodes de traitement de troubles ophtalmiques
EP3790557A4 (fr) Compositions et méthodes pour améliorer la distorsion de brin
EP3844500A4 (fr) Compositions de rp182 et procédés
EP3801478A4 (fr) Méthodes et compositions pour la prévention ou le traitement de la calciphylaxie
EP3830196A4 (fr) Compositions et procédés de traitement de surface
EP3618850A4 (fr) Compositions et méthodes de traitement de pathologies oculaires
EP3801534A4 (fr) Compositions et procédés pour augmenter l&#39;exposition au plasma de tétrahydrobioptérine
EP3752161A4 (fr) Méthodes de traitement de la fibrose
EP3755328A4 (fr) Compositions et méthodes de traitement du prurit
EP3801620A4 (fr) Compositions et méthodes de traitement de la pancréatite
EP3990394A4 (fr) Compositions et procédés de traitement des eaux usées
EP3870210A4 (fr) Compositions et procédés de traitement ou de prévention de la fibrose
EP3883995A4 (fr) Compositions polymères expansées par extrusion et procédés de fabrication de compositions polymères expansées par extrusion
EP3856195A4 (fr) Procédés et compositions pour traiter des troubles liés au vieillissement au moyen d&#39;inhibiteurs de ccr3
EP3921286A4 (fr) Procédés et compositions pour le traitement d&#39;eau produite
EP3917320A4 (fr) Compositions et procédés bactéricides

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210325

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RAV Requested validation state of the european patent: fee paid

Extension state: MD

Effective date: 20210325

Extension state: MA

Effective date: 20210325

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031535000

Ipc: A61K0031454500

A4 Supplementary search report drawn up and despatched

Effective date: 20220520

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 45/06 20060101ALI20220516BHEP

Ipc: A61P 25/16 20060101ALI20220516BHEP

Ipc: A61P 25/00 20060101ALI20220516BHEP

Ipc: A61K 9/00 20060101ALI20220516BHEP

Ipc: A61K 47/00 20060101ALI20220516BHEP

Ipc: A61K 33/00 20060101ALI20220516BHEP

Ipc: A61K 31/00 20060101ALI20220516BHEP

Ipc: A61P 1/00 20060101ALI20220516BHEP

Ipc: A61K 31/4545 20060101AFI20220516BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20231201